Positive Results for Acelyrin's Lonigutamab in TED Study

Acelyrin, Inc. (NASDAQ: SLRN) has announced positive proof-of-concept data from an ongoing phase 1/2 trial of lonigutamab in thyroid eye disease (TED). Lonigutamab, a subcutaneously delivered humanized igg1 monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), demonstrated rapid improvements in proptosis and clinical activity score (CAS) at the first measurement within three weeks after the first subcutaneous dose.

The phase 1/2 trial, which is evaluating the safety and efficacy of lonigutamab dosed in TED patients, showed promising results. In cohort 1, which was placebo-controlled, 50% of patients receiving lonigutamab at 40mg every three weeks (q3w) achieved a proptosis response of ≥ 2 millimeter reduction from baseline, while 67% achieved a clinical activity score (CAS) response of ≥ 2 point reduction. In cohort 2, which is open label, patients receiving a 50mg loading dose followed by 25mg every week (qw) achieved a 50% proptosis response and an 83% CAS response. Furthermore, 25% of patients in cohort 2 achieved a diplopia response, indicating a clinically meaningful improvement.

The safety profile of lonigutamab has been favorable, with no reports of hyperglycemia or hearing impairment and no serious adverse events reported. Dr. Shao-Lee Lin, Founder and CEO of Acelyrin, expressed enthusiasm about the results, emphasizing the potential of lonigutamab to move patients towards resolution of their disease.

The positive data from the phase 1/2 trial have paved the way for a phase 2b/3 trial, which is planned to be initiated in the second half of 2024. This trial is designed to be the first of two registrational trials in TED, indicating a significant step forward in the clinical development of lonigutamab.

Today the company's shares have moved 4.3% to a price of $8.3. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.